Treatment of cervical dystonia using shorter incobotulinumtoxinA injection intervals improves patient-reported outcomes in those with inadequate benefits from standard intervals
Objective: To assess the impact of 2 different injection schedules of incobotulinumtoxinA on patient-reported assessments in cervical dystonia (CD). Background: There is individual variation in…Absence of neutralizing antibody formation during incobotulinumtoxinA treatment of spasticity in botulinum toxin-naïve children with cerebral palsy: pooled analysis of Phase 3 studies
Objective: To investigate neutralizing antibody (NAb) formation in three large Phase 3 studies with incobotulinumtoxinA, a botulinum neurotoxin type A (BoNT-A) with no complexing proteins,…Efficacy and safety of incobotulinumtoxinA for upper- or combined upper- and lower-limb spasticity in children/adolescents with cerebral palsy: the XARA study
Objective: To assess the efficacy/safety of incobotulinumtoxinA for upper- and combined upper-/lower-limb spasticity in ambulant and non-ambulant children/adolescents with cerebral palsy (CP). Background: Spastic CP…Improvement of spasticity-related pain with incobotulinumtoxinA treatment in children/adolescents with cerebral palsy: pooled analysis of Phase 3 studies
Objective: To assess the effect of incobotulinumtoxinA on spasticity-related pain (SRP) using pooled data from three large Phase 3 pediatric studies. Background: In children/adolescents with…Cost-Utility Analysis of Flexible Intervals with IncobotulinumtoxinA Versus Fixed Dosing with OnabotulinumtoxinA in the Management of Cervical Dystonia and Blepharospasm in Major Canadian Markets
Objective: The aim was to carry out a cost-utility analysis for IncobotulinumtoxinA (INCO) administered with flexible treatment intervals compared to onabotulinumtoxinA (ONA) administered with fixed…Cost-Analysis of the Use of IncobotulinumtoxinA and AbobotulinumtoxinA for the Treatment of Post-Stroke Upper Limb Spasticity Based on Recommended Dosing for Muscles and Clinical Patterns
Objective: To carry out a cost-analysis based on the respective recommended dosing per muscle using IncobotulinumtoxinA (INCO) and AbobotulinumtoxinA (ABO) for the treatment of post-stroke…IncobotulinumtoxinA is effective, long lasting and well tolerated treatment of hemifacial spasm
Objective: Hemifacial spasm (HFS) is a common movement disorder characterized by involuntary contractions of the muscles innervated by facial nerve. Background: To evaluate the effect…Development of a patient-reported Botulinum Toxin Response Scale (BTRS) for neurological disorders: a feasibility study.
Objective: To assess the feasibility of developing a patient-reported Botulinum Toxin Response Scale (BTRS) for different neurological conditions. Background: Botulinum toxin (BoNT) is a highly…Tardive Cervical Dystonia: Treatment with Botulinum: Treatment with Botulinum Toxin Guided by Electromyography
Objective: To describe the use of botulinum toxin in the treatment of tardive dystonia. Background: Tardive dystonia (TD) was recognized as a complication of dopamine…Efficacy of incobotulinumtoxinA in patients with sialorrhea, as assessed using the modified Radboud Oral Motor Inventory for Parkinson’s disease (mROMP): Results of the SIAXI study
Objective: The pivotal double-blind, randomised Phase III SIAXI study (NCT02091739), assessed the efficacy and safety of incobotulinumtoxinA 75 or 100 U for sialorrhea. Co-primary endpoints…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.